Pharmacokinetics and Pharmacodynamics Practice Questions

Q: The following curve shows a graded dose-response curve. Drug A and drug B are bronchodilators. What do drug C and D represent?

C = Competitive antagonist, D = Noncompetitive antagonist. ***C = Competitive antagonist, D = Noncompetitive antagonist*** - Curve C, representing a **competitive antagonist**, shifts the dose-response curve of the agonist to the **right** without reducing the maximal effect. This indicates that a higher concentration of the agonist is needed to overcome the antagonist and achieve the same maximal response. - Curve D, representing a **noncompetitive antagonist**, reduces the **maximal effect** of the agonist and does not significantly shift the curve to the right in the same manner as a competitive antagonist would for the full maximal effect of the agonist. The maximal effect is *permanently* reduced even with increasing agonist concentration. *Noncompetitive antagonist, D = Competitive antagonist* - This is incorrect because a **noncompetitive antagonist** reduces the maximal effect, which is depicted by curve D, while a **competitive antagonist** shifts the curve to the right without reducing maximal effect, as seen in curve C. - The roles of C and D are reversed in this option. *C = Agonist, D = Partial agonist* - This is incorrect as C and D are clearly shown to be modulating the effect of "bronchodilators" (A and B), indicating they are likely antagonists affecting the primary drugs, not agonists themselves. - A **partial agonist** would produce a lower maximal effect than a full agonist, but would still show a dose-response curve with an increasing effect, not a flat line limiting the maximal effect like D. *C = Agonist, D = Competitive antagonist* - This is incorrect as C represents a shift in the agonist's curve, typical of a **competitive antagonist**, not an agonist itself. - If C were an agonist, it would have its own dose-response curve showing increasing effect, similar to A and B.

Q: What do A and B represent in the curve shown below?

A= Median effective dose, B= Median lethal dose. ***A= Median effective dose, B= Median lethal dose*** - **A** corresponds to the **median effective dose (ED50)**, which is the dose that produces a therapeutic effect in 50% of the population - The purple curve represents the dose-response for efficacy; at A, 50% of individuals are responding effectively - **B** corresponds to the **median lethal dose (LD50)**, which is the dose that is lethal to 50% of the population - The red curve represents the dose-response for toxicity/lethality; at B, 50% of individuals are experiencing a lethal outcome *A= Therapeutic index, B= Median efficacy* - The **therapeutic index** is a ratio (LD50/ED50), not a specific dose represented on the x-axis - **Median efficacy** is not a standard pharmacological term to represent a point on a dose-response curve; rather, efficacy refers to the maximal effect a drug can produce *A= Median lethal dose, B= Median effective dose* - This option reverses the correct identification of A and B - **Median effective dose (ED50)** is typically expected at lower doses, while **median lethal dose (LD50)** is at higher doses, indicating toxicity - In the provided graph, the curve for A occurs at a much lower dose range than the curve for B, making it the effective dose, not the lethal dose *A= Median efficacy, B= Therapeutic index* - **Median efficacy** is not a specific dose value represented this way on a dose-response curve - The **therapeutic index** is a ratio, not a dose point on the graph

Q: Brand A of liposomal amphotericin B is of innovator company and brand B is of a generic company. AUC of Brand A is 124 mg.h/L and AUC of brand B is 115 mg.h/L. Which of the following statements is correct?

Brand A is bioequivalent to brand B. ***Brand A is bioequivalent to brand B*** - **Bioequivalence** is generally established if the **90% confidence interval** for the ratio of the **AUC** (and Cmax) of the test product (Brand B) to the reference product (Brand A) falls within **80-125%**. - Here, the ratio of AUC (Brand B / Brand A) is 115/124 ≈ 0.927 or 92.7%. This value falls well within the accepted range of 80-125%, indicating bioequivalence. *Brand A is not bioequivalent to brand B* - This statement is incorrect because the AUC ratio (115/124 ≈ 0.927) is within the **standard bioequivalence range of 80-125%**, indicating that the two brands are indeed bioequivalent. - While there are differences in Cmax and Tmax for the two brands as shown in the graph, the provided AUC values suggest bioequivalence for the overall drug exposure. *Brand A has higher volume of distribution than brand B* - The provided **AUC values** (Area Under the Curve) primarily reflect the **extent of drug exposure** and are not directly indicative of the **volume of distribution (Vd)**. - Vd is a pharmacokinetic parameter that relates the total amount of drug in the body to the concentration of the drug in plasma, and it cannot be directly inferred from AUC values alone without additional information like dose and clearance. *Brand B has higher volume of distribution than brand A* - Similar to the previous option, AUC values alone are insufficient to determine the relative **volume of distribution** between the two brands. - Changes in Vd would affect the peak concentration (Cmax) and the elimination half-life, but a definitive conclusion requires more comprehensive pharmacokinetic analysis.

Q: The following plot of log dose of norepinephrine on X-axis and response in the form of increase in cardiac contractility on Y-axis represents?

Graded dose response curve. ***Graded dose response curve*** - This graph shows a **continuous increase in response** (cardiac contractility) as the **log dose of norepinephrine increases**, which is characteristic of a graded dose-response curve. - A graded dose-response curve represents the **magnitude of effect** observed from a single biological unit (e.g., cell, tissue, or individual) as a function of the drug dose. *Dose response curve* - This is a general term, but more specific labels like 'graded' or 'quantal' are used to distinguish the type of response measured. - It does not specify whether the response measured is continuous or all-or-none. *Quantal dose response curve* - A quantal dose-response curve describes the **percentage of a population** that exhibits a specific **all-or-none effect** at a given dose. - It would typically show the cumulative percentage of individuals responding as a function of dose, not a continuous response within a single unit. *Quantum dose response curve* - "Quantum dose response curve" is not a standard pharmacological term. - This term is likely a misspelling or incorrect interpretation of 'quantal dose response curve'.

Q: Which of the following statement is correct regarding the given DRC? (AllMS Nov 2016)

A and B are full agonists. ***A and B are full agonists*** - Both Drug A and Drug B reach the **maximum biological effect**, indicated as 100 on the y-axis, meaning they are capable of producing the full response. - A full agonist is a substance that binds to a receptor and produces the **maximum possible biological response**. *C is non-competitive antagonist* - Drug C *does* produce a biological effect, albeit a lower one, making it a **partial agonist**, not an antagonist. - A non-competitive antagonist would **reduce the maximum effect** of the agonist and shift the curve downwards, which is not what is observed here for C. *B is more potent than A* - Drug A achieves 50% of its maximal effect at a **lower concentration** than Drug B (i.e., further to the left on the x-axis). - Therefore, Drug A is **more potent** than Drug B, as potency is inversely related to the concentration required for a given effect. *A is more efficacious than B* - Both Drug A and Drug B reach the **same maximum biological effect** (100 on the y-axis), indicating they have equal efficacy. - Efficacy refers to the **maximum effect** a drug can produce, regardless of the dose.

Q: The maximum safe dose for Lignocaine (without adrenaline) as a local anaesthetic drug is :

3 mg/kg. ***3 mg/kg*** - The maximum safe dose for **plain lignocaine** (without adrenaline) is **3 mg/kg**. - Exceeding this limit increases the risk of **systemic toxicity**, particularly central nervous system and cardiovascular effects. *7 mg/kg* - This dosage refers to the maximum safe dose of **lignocaine when combined with adrenaline**. - **Adrenaline causes vasoconstriction**, which delays systemic absorption of lignocaine, allowing for a higher total dose. *5 mg/kg* - This is also within the range of the maximum safe dose for **lignocaine with adrenaline**, though it is sometimes quoted as the upper limit for **plain lignocaine** by some references. - However, for plain lignocaine, **3 mg/kg is the more widely accepted and safer standard**. *9 mg/kg* - This dose is **significantly higher** than the recommended maximum for both plain and adrenaline-containing lignocaine. - Administering 9 mg/kg would carry a **very high risk of severe systemic toxicity**, including convulsions and cardiac arrest.

Q: Choose the correct options regarding the route of administration and bioavailability. A- Intravenous =1 B- 0.75< Oral <1 C-0.75 <IM ≤ 1 D- 0.75<SC ≤ 1 IM - Intramuscular SC- Subcutaneous

A, C, D. ***A, C, D*** - Intravenous (IV) administration has **100% bioavailability** because the drug enters the systemic circulation directly, bypassing any absorption barriers. - Intramuscular (IM) and subcutaneous (SC) routes generally have **high bioavailability**, often between 75% and 100%, as drugs are absorbed directly into the bloodstream without first-pass metabolism. *A and D* - While options A and D are correct, this choice is incomplete as option C is also a correct statement regarding bioavailability. - IM administration typically results in high systemic bioavailability, similar to SC, making its exclusion here incorrect. *A and C* - While options A and C are correct, this choice is incomplete as option D is also a correct statement regarding bioavailability. - Subcutaneous administration also generally results in high bioavailability, as absorption tends to be complete. *A, B, D* - While options A and D are correct, option B is typically incorrect for oral bioavailability. - Oral bioavailability of many drugs is often less than 0.75 (75%) due to factors like **first-pass metabolism** and incomplete absorption in the gastrointestinal tract.

Question 1

Which is correct about the curves shown?

Accepted Answer

A= Graded dose response curve, B= Dose response curve

Answer

A= Dose response curve, B= Graded dose response curve

Answer

A= Quantal dose response curve, B= Dose response curve

Answer

A= Dose response curve, B= Quantal dose response curve

Question 2

The following curve shows a graded dose-response curve. Drug A and drug B are bronchodilators. What do drug C and D represent?

Accepted Answer

C = Competitive antagonist, D = Noncompetitive antagonist

Answer

C = Noncompetitive antagonist, D = Competitive antagonist

Answer

C = Agonist, D = Partial agonist

Answer

C = Agonist, D = Competitive antagonist

Question 3

What do A and B represent in the curve shown below?

Accepted Answer

A= Median effective dose, B= Median lethal dose

Answer

A= Therapeutic index, B= Median efficacy

Answer

A= Median lethal dose, B= Median effective dose

Answer

A= Median efficacy, B= Therapeutic index

Question 4

Brand A of liposomal amphotericin B is of innovator company and brand B is of a generic company. AUC of Brand A is 124 mg.h/L and AUC of brand B is 115 mg.h/L. Which of the following statements is correct?

Accepted Answer

Brand A is bioequivalent to brand B

Answer

Brand A is not bioequivalent to brand B

Answer

Brand A has higher volume of distribution than brand B

Answer

Brand B has higher volume of distribution than brand A

Question 5

The following plot of log dose of norepinephrine on X-axis and response in the form of increase in cardiac contractility on Y-axis represents?

Accepted Answer

Graded dose response curve

Answer

Dose response curve

Answer

Quantal dose response curve

Answer

Quantum dose response curve

Question 6

Which of the following statement is correct regarding the given DRC? (AllMS Nov 2016)

Accepted Answer

A and B are full agonists

Answer

C is non-competitive antagonist

Answer

B is more potent than A

Answer

A is more efficacious than B

Question 7

The maximum safe dose for Lignocaine (without adrenaline) as a local anaesthetic drug is :

Accepted Answer

3 mg/kg

Answer

7 mg/kg

Answer

5 mg/kg

Answer

9 mg/kg

Question 8

Which of the following statements is correct regarding the given graph?

Accepted Answer

Drug 1 represents agonist and drug 4 represents inverse agonist

Answer

Drug 1 represents agonist and drug 2 represents inverse agonist

Answer

Drug 3 represents agonist and drug 4 represents inverse agonist

Answer

Drug 2 represents partial agonist and drug 3 represents inverse agonist

Question 9

Which of the following is true about clinical therapeutic index?

Accepted Answer

Dose in which efficacy and toxicity can be balanced in an individual

Answer

Therapeutic index is LD50/ED50

Answer

It is only used for a specific individual

Answer

It measures therapeutic index in populations rather than individuals

Question 10

Choose the correct options regarding the route of administration and bioavailability.
A- Intravenous =1
B- 0.75< Oral <1
C-0.75 <IM ≤ 1
D- 0.75<SC ≤ 1
IM - Intramuscular
SC- Subcutaneous

Accepted Answer

A, C, D

Answer

A and D

Answer

A and C

Answer

A, B, D

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?